SCHEMBL7718882

SCHEMBL7718882

CCOC(=O)C(CC)CC(C)P(=O)(O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 2/20 0.36
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
KMT2A Q03164 1/20 0.34
EPHX2 P34913 7/20 0.34
PPARG P37231 3/20 0.34
ALDH1A1 P00352 3/20 0.33
CPB2 Q96IY4 1/20 0.33
LAP3 P28838 1/20 0.33
TSHR P16473 2/20 0.33
CYP3A4 P08684 1/20 0.33
ALOX15 P16050 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP3 P08254 1/20 0.32
USP2 O75604 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7715879 0.82 HSD17B10 (0.38) CYP2D6CYP2C9CYP2C19HSD17B10MEN1
Phosphoric Acid SCHEMBL27426833 0.80 ALDH1A1 (0.42) CYP2D6CYP2C9CYP2C19HSD17B10MEN1
SCHEMBL7716769 0.79 CYP2D6 (0.42) CYP2D6CYP2C9CYP2C19HSD17B10MEN1
SCHEMBL13555039 0.78 CPA1 (0.44) CYP2C19HSD17B10MEN1NPC1KMT2A
SCHEMBL13541257 0.78 CPA1 (0.44) CYP2C19HSD17B10MEN1NPC1KMT2A
SCHEMBL17617124 0.78 CPA1 (0.44) CYP2C19HSD17B10MEN1NPC1KMT2A
SCHEMBL7718908 0.77 CYP2D6 (0.40) CYP2D6CYP2C9CYP2C19HSD17B10MEN1
SCHEMBL7718813 0.76 CYP2D6 (0.44) CYP2D6CYP2C9CYP2C19MEN1NPC1
SCHEMBL284647 0.75 ALDH1A1 (0.50) HSD17B10MEN1NPC1KMT2AEPHX2
SCHEMBL12019115 0.75 CYP3A4 (0.44) CYP2C19HSD17B10MEN1NPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
EP-0315399-B1 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE POULENC RORER INT (US) 1996-01-10 EP disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed